Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Per Soelberg Soerensen"'
Autor:
Olaf Stuve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert, Doris Damian, Fernando Dangond, Ursula Boschert
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension). This ana
Externí odkaz:
https://doaj.org/article/3e794422ef8647f79e50ceb14af5097d
Autor:
Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot
Publikováno v:
CNS Drugs
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db23efcded486e57c8c7b3dd1b8db8cf
http://hdl.handle.net/11585/853457
http://hdl.handle.net/11585/853457
Autor:
Olaf Stüve, Fernando Dangond, Gavin Giovannoni, Per Soelberg Soerensen, Doris Damian, Thomas Leist, Ursula Boschert, Yann Hyvert
Publikováno v:
Stuve, O, Soelberg Soerensen, P, Leist, T, Giovannoni, G, Hyvert, Y, Damian, D, Dangond, F & Boschert, U 2019, ' Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis : an extended analysis of surface markers ', Therapeutic Advances in Neurological Disorders, vol. 12, pp. 1-16 . https://doi.org/10.1177/1756286419854986
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Therapeutic Advances in Neurological Disorders
Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension). This ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e493e28ed11ce2cbf1b9505cb54b2db6
https://curis.ku.dk/portal/da/publications/effects-of-cladribine-tablets-on-lymphocyte-subsets-in-patients-with-multiple-sclerosis(1e7f9850-4084-4f2a-a9dc-4b9c3e2c5873).html
https://curis.ku.dk/portal/da/publications/effects-of-cladribine-tablets-on-lymphocyte-subsets-in-patients-with-multiple-sclerosis(1e7f9850-4084-4f2a-a9dc-4b9c3e2c5873).html
Autor:
Robert P. Lisak, Michael E. Selzer, Douglas W. Zochodne, François Boller, Richard T. Johnson, Mark Hallett, Vladimir Hachinski, John Newsom-Davis, Anthony E. Lang, Christopher Kennard, Timothy A. Pedley, Robert C. Griggs, Per Soelberg Soerensen, Roger N. Rosenberg, Michael J. Aminoff, Andrew J. Lees
Publikováno v:
Movement Disorders. 17:3-4
Autor:
Roger N. Rosenberg, Vladimir Hachinski, Timothy A. Pedley, Richard T. Johnson, Douglas Zochodne, Andrew Lees, Per Soelberg Soerensen, Mark Hallett, Michael J. Aminoff, François Boller, John Newsom-Davis, Anthony E. Lang, Robert C. Griggs, Michael E. Selzer, Christopher Kennard, Robert Lisak
Publikováno v:
Archives of Neurology. 59:27
Autor:
Per Soelberg Soerensen, Claus Kamby
Publikováno v:
Journal of neuro-oncology. 6(1)
The clinical course of 106 patients with brain metastases from breast cancer was retrospectively studied. Median time of survival after detection of intracranial metastases (SAR(ICM)) was 14 weeks (95% confidence limits: 10–19 weeks), and 25% of th